Why Enveda Teaches AI to Read Nature's Chemistry

Isn’t it crazy to think that half of FDA-approved small molecule drugs have roots in nature? But José Trevejo, Chief Medical Officer at Enveda, says the opportunity now is not to romanticize that history, but to make it usable at modern speed. In this episode of Power to the Patients, Brandon Li speaks with José about AI-assisted drug discovery, mass spectrometry, ENV-294 and why the real bottleneck in biotech may no longer be finding molecules. It may be scaling the trials to test them. By combining ancient healing stories with high-throughput technology, researchers now identify these candidates in hours rather than years. This clinical acceleration is rewriting the early-stage discovery playbook.